Semaglutide vs Zepbound: Which GLP-1 Is Right for You?

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting any new medication or treatment program.*

---

If you have been researching GLP-1 weight loss medications, you have probably heard about Zepbound. It has been in the news, mentioned by doctors, and searched by millions of people trying to figure out whether it is more effective than semaglutide, the active ingredient in Wegovy and Ozempic.

Here is the honest answer: Zepbound (tirzepatide) shows greater average weight loss than semaglutide in clinical trials, including a direct head-to-head study published in 2025. But that is not the whole story, and "greater on average" does not always mean "better for you specifically."

This guide breaks down how they compare, what the research shows, and what factors you and your provider should weigh together.

---

What Is Zepbound?

Zepbound is a brand-name prescription medication made by Eli Lilly. Its active ingredient is tirzepatide. The FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity (BMI of 30 or above) or adults with overweight (BMI of 27 or above) who have at least one weight-related health condition.

Zepbound and Mounjaro are both tirzepatide products from Eli Lilly, approved under separate FDA indications: Mounjaro for type 2 diabetes and Zepbound specifically for chronic weight management.

Semaglutide, on the other hand, is the active ingredient in Wegovy (weight management) and Ozempic (type 2 diabetes). Both tirzepatide and semaglutide are given as weekly subcutaneous injections.

---

How They Work: One Hormone vs Two

This is the core scientific difference between the two medications.

Semaglutide: GLP-1 Only

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your brain you are full, slows gastric emptying so food leaves your stomach more slowly, and stimulates insulin release to regulate blood sugar.

By mimicking this hormone, semaglutide reduces appetite and caloric intake. It is effective. But it only activates one pathway.

Tirzepatide (Zepbound): GLP-1 Plus GIP

Tirzepatide activates two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone involved in energy metabolism and fat storage.

This dual mechanism is why researchers refer to tirzepatide as a "twincretin." Activating both pathways produces greater appetite suppression and metabolic effects than either hormone alone. This is the mechanism behind the stronger weight loss numbers in clinical trials.

---

What the Research Actually Shows

Semaglutide: STEP 1 Trial

The landmark trial for semaglutide in weight management is STEP 1, published in the *New England Journal of Medicine* in 2021. In 1,961 adults with obesity or overweight, weekly semaglutide 2.4mg produced an average weight loss of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. Both groups received lifestyle counseling ([PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)).

For someone starting at 220 pounds, that is roughly 33 pounds on average.

The SELECT trial (2023) added an important finding beyond weight loss: semaglutide reduced major cardiovascular events by 20% in people with established cardiovascular disease and overweight or obesity, even in those without diabetes ([PMID: 37960388](https://pubmed.ncbi.nlm.nih.gov/37960388/)). No comparable cardiovascular outcomes trial for tirzepatide has been completed yet.

Tirzepatide (Zepbound): SURMOUNT-1 Trial

The SURMOUNT-1 trial, published in 2022, is the key study for tirzepatide. At the highest dose (15mg weekly), tirzepatide produced an average weight loss of 22.5% over 72 weeks in adults with obesity or overweight ([PMID: 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/)).

At 10mg, the average was 21.4%. At 5mg, 16%.

For someone starting at 220 pounds, 22.5% weight loss is roughly 50 pounds on average at the highest dose.

The Head-to-Head: SURMOUNT-5

The most useful comparison came in 2025. The SURMOUNT-5 trial directly compared tirzepatide (10mg/15mg) against semaglutide 2.4mg in adults with obesity. Results at 72 weeks:

• Tirzepatide: 20.2% average weight loss
• Semaglutide: 13.7% average weight loss

The difference was statistically significant ([PMID: 39764728](https://pubmed.ncbi.nlm.nih.gov/39764728/)).

That is a meaningful gap. And yet: individual response varies considerably. Some people lose far more on semaglutide than the trial average. Some do not tolerate tirzepatide well. Your personal health history often matters more than population averages.

---

Side Effect Comparison

Both medications work on overlapping gut and brain pathways, so their side effect profiles are similar.

Notably, in the SURMOUNT-5 head-to-head study, fewer people stopped tirzepatide due to gastrointestinal side effects (6.6%) compared to semaglutide (8.0%). But the raw nausea rates are lower for tirzepatide in individual trials, which some clinicians attribute to slower dose titration in the tirzepatide protocols.

Serious Side Effects (Both Medications)

These are less common but important to understand before starting either medication:

• Pancreatitis: Seek immediate care for severe abdominal pain
• Gallbladder disease: Gallstones are more common with rapid weight loss
• Vision changes: Report any new visual symptoms to your provider promptly
• Thyroid tumors: Animal studies showed thyroid C-cell tumors with GLP-1 agonists. Human risk is uncertain but both medications carry a boxed warning. Neither is recommended for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Both medications should only be used under provider supervision with ongoing monitoring.

---

Cost Comparison: Brand vs Compounded

Brand-name pricing without insurance is significant for both medications:

Insurance coverage exists but is unpredictable. Many insurance plans require prior authorization, and coverage policies change. Some patients who start on brand-name medications find their coverage is later denied or limited.

Compounded Alternatives

Compounded semaglutide and tirzepatide are available through licensed 503A compounding pharmacies at significantly lower cost. At Prescriva, pricing starts at:

• Compounded semaglutide: $159 per month
• Compounded tirzepatide: $179 per month

Both bundle consultation, medication, and shipping into a single monthly charge.

Important: Compounded medications are not FDA-approved and are not the same products as Wegovy, Ozempic, Zepbound, or Mounjaro. They are prepared under a separate regulatory pathway and have not been separately evaluated by the FDA for safety or efficacy. This is a real distinction, and anyone considering compounded medications should understand it fully.

For many people, the cost difference between brand and compounded is the deciding practical factor. For others, the FDA approval status of brand-name medications matters significantly. This is a conversation worth having with your provider.

---

Zepbound vs Semaglutide: Which Is Right for You?

There is no universal answer. Here are the factors your provider will weigh:

Zepbound (tirzepatide) may be a better fit if:

• Maximum weight loss is your primary goal and you meet eligibility
• You have type 2 diabetes (tirzepatide has strong data in this population from SURMOUNT-2, [PMID: 37433641](https://pubmed.ncbi.nlm.nih.gov/37433641/))
• You have not responded adequately to semaglutide in the past
• You tolerate weekly injections and the tirzepatide titration schedule

Semaglutide may be a better fit if:

• You have established cardiovascular disease. Semaglutide has a completed cardiovascular outcomes trial (SELECT) showing a 20% reduction in major cardiac events. A comparable trial for tirzepatide has not been completed.
• You have prior good experience with lower-dose semaglutide for diabetes and want to continue with a semaglutide-based regimen
• Your provider has more experience managing semaglutide protocols
• Cost or insurance coverage makes semaglutide more accessible in your situation

Neither may be appropriate if:

• You have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• You have a history of severe pancreatitis
• You are pregnant, planning pregnancy, or breastfeeding
• You have certain other conditions your provider will evaluate

This list is not exhaustive. A thorough medical evaluation is necessary before starting either medication.

---

Frequently Asked Questions

Is Zepbound better than semaglutide for weight loss?

On average in clinical trials, yes. Tirzepatide (Zepbound) produces greater average weight loss than semaglutide, including in a 2025 head-to-head study (SURMOUNT-5). But individual response varies, and your health history, other medications, and personal tolerance matter more than population averages.

Is Zepbound the same as tirzepatide?

Yes. Zepbound is the brand name for tirzepatide, manufactured by Eli Lilly and approved for chronic weight management. Mounjaro is also a tirzepatide product from Eli Lilly, approved under a separate indication for type 2 diabetes.

What is the difference between Wegovy and Zepbound?

Wegovy contains semaglutide (made by Novo Nordisk). Zepbound contains tirzepatide (made by Eli Lilly). They work on different receptor pathways and have different clinical trial data, though both are FDA-approved for weight management.

Can I get compounded tirzepatide instead of Zepbound?

Compounded tirzepatide is available through licensed compounding pharmacies. It is not the same product as Zepbound, is not FDA-approved, and has not been separately evaluated by the FDA. At Prescriva, compounded tirzepatide starts at $179/month, compared to approximately $1,000 to $1,300/month for brand-name Zepbound without insurance.

How long does it take to see results on either medication?

Most people notice reduced appetite within the first few weeks. Meaningful weight loss typically becomes visible at 4 to 8 weeks, with ongoing results continuing through 12 to 24 months in clinical trials. Results depend on adherence, lifestyle changes, and individual factors. Results vary.

Do I need to change my diet?

Clinical trial data for both medications consistently includes lifestyle intervention alongside the medication. GLP-1 medications reduce appetite. Healthy eating and physical activity habits help sustain and maximize results.

---

The Bottom Line

Zepbound (tirzepatide) shows greater average weight loss than semaglutide in clinical trials, including a direct head-to-head comparison. For many people, especially those with significant weight to lose or those who have not responded well to semaglutide, this difference is clinically meaningful.

Semaglutide has a longer track record, more cardiovascular outcome data, and remains the right choice for many people, particularly those with established heart disease.

The good news: you do not have to figure this out alone. A licensed healthcare provider can review your full health picture and help you understand which medication, at which dose, makes sense for your situation.

At Prescriva, every prescription is written by a licensed clinician who reviews your complete health history. If you qualify, your treatment plan is personalized to you. If you do not qualify, you will be told that clearly and not charged.

Ready to find out where you stand? Start your eligibility evaluation at Prescriva. It takes about 10 minutes, and a clinician reviews your information before any treatment is prescribed.

---

*This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and are not the same as, equivalent to, or interchangeable with FDA-approved brand-name medications. Individual results may vary. Always consult a licensed healthcare provider before starting any new treatment.*

*All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.*

*Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.*

---

References

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med.* 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med.* 2022;387(3):205-216. [PMID: 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/)
3. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med.* 2023;389(24):2221-2232. [PMID: 37960388](https://pubmed.ncbi.nlm.nih.gov/37960388/)
4. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). *Lancet.* 2023;402(10402):613-626. [PMID: 37433641](https://pubmed.ncbi.nlm.nih.gov/37433641/)
5. Rubino DM, et al. Tirzepatide vs semaglutide in adults with overweight or obesity (SURMOUNT-5). *N Engl J Med.* 2025. [PMID: 39764728](https://pubmed.ncbi.nlm.nih.gov/39764728/)